Bio Path Book Value Per Share vs. Current Ratio

BPTH Stock  USD 0.64  0.02  3.23%   
Considering the key profitability indicators obtained from Bio Path's historical financial statements, Bio Path Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Bio Path's ability to earn profits and add value for shareholders.
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
0.92259414
Current Value
0.88
Quarterly Volatility
194.36019343
 
Credit Downgrade
 
Yuan Drop
 
Covid
The Bio Path's current Sales General And Administrative To Revenue is estimated to increase to 179.88, while Price To Sales Ratio is projected to decrease to 471.68. The Bio Path's current Change To Netincome is estimated to increase to about 991.4 K, while Operating Income is forecasted to increase to (15.1 M).
For Bio Path profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bio Path to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bio Path Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bio Path's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bio Path Holdings over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.34)
Return On Assets
(1.40)
Return On Equity
(3.66)
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bio Path Holdings Current Ratio vs. Book Value Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bio Path's current stock value. Our valuation model uses many indicators to compare Bio Path value to that of its competitors to determine the firm's financial worth.
Bio Path Holdings is rated below average in book value per share category among its peers. It is rated fifth in current ratio category among its peers fabricating about  21.81  of Current Ratio per Book Value Per Share. As of now, Bio Path's Book Value Per Share is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Path's earnings, one of the primary drivers of an investment's value.

Bio Current Ratio vs. Book Value Per Share

Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Bio Path

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.71 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Bio Path

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
15.57 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Bio Current Ratio Comparison

Bio Path is currently under evaluation in current ratio category among its peers.

Bio Path Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bio Path, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bio Path will eventually generate negative long term returns. The profitability progress is the general direction of Bio Path's change in net profit over the period of time. It can combine multiple indicators of Bio Path, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-15.8 M-15.1 M
Income Before Tax-16.1 M-15.3 M
Total Other Income Expense Net-235 K-223.2 K
Net Loss-16.1 M-15.3 M
Income Tax Expense-29.7 K-31.2 K
Net Loss-16.7 M-15.8 M
Non Operating Income Net Other29.9 K28.4 K
Net Loss-9.4 M-9.9 M
Interest Income52 K31 K
Net Interest Income52 K32.5 K
Change To Netincome944.1 K991.4 K
Net Loss(33.64)(35.32)
Income Quality 0.72  0.66 
Net Income Per E B T 1.15  1.10 

Bio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bio Path. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bio Path position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bio Path's important profitability drivers and their relationship over time.

Use Bio Path in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Path position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will appreciate offsetting losses from the drop in the long position's value.

Bio Path Pair Trading

Bio Path Holdings Pair Trading Analysis

The ability to find closely correlated positions to Bio Path could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Path when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Path - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Path Holdings to buy it.
The correlation of Bio Path is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Path moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Path Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Path can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bio Path position

In addition to having Bio Path in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:
Check out Trending Equities.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
To fully project Bio Path's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bio Path Holdings at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bio Path's income statement, its balance sheet, and the statement of cash flows.
Potential Bio Path investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bio Path investors may work on each financial statement separately, they are all related. The changes in Bio Path's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bio Path's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.